Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Skye Bioscience Inc (OP: SKYE ) N/A UNCHANGED Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Skye Bioscience Inc < Previous 1 2 Next > Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down December 19, 2022 MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January. Via Benzinga Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma November 16, 2022 Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial... Via Benzinga Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma September 20, 2022 Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has... Via Benzinga Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma July 25, 2022 Modern cannabis research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC). Mechoulam later also elucidated... Via Benzinga Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer July 21, 2022 Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing... Via Benzinga Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids April 08, 2021 Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this artic... Via Benzinga Topics Cannabis Exposures Cannabis Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details May 12, 2022 Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc. Via Benzinga Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma March 03, 2022 Skye Bioscience, Inc. (OTCQB:SKYE) has entered into... Via Benzinga Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics December 23, 2021 Skye Bioscience Announces Board Additions & Promotions CBD-focused biopharmaceutical company Skye Bioscience, Inc. Via Benzinga These OTC Securities Had the Most Trading Activity in June July 20, 2021 Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... Via Benzinga Topics Cannabis Exposures Cannabis Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour July 08, 2021 Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane... Via Benzinga Topics Cannabis Exposures Cannabis < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.